Skip navigation

Orexigen shares climb after study data announced

Orexigen Therapeutics Inc. said Monday information from a late-stage study showed that patients taking its potential diet drug Contrave maintained normal blood pressure patterns around the clock during a year of treatment. Full story

Factbox: A troubled history for weight-loss drugs

A proposed diet drug from Orexigen Therapeutics was rejected by U.S. regulators who requested a clinical trial to resolve concerns about heart risk, the company said on Tuesday. Full story

Online diet pills -- the next drug safety 'catastrophe'?

More and more, weight loss products are being "adulterated" with potentially dangerous ingredients by their manufacturers. Full story

Obesity Drug Plays

   Cory Kasimov, an anaylst at JPMorgan, shares his best trades in the obesity drug space.

Orexigen's Big Drug Win

   Orexigen shares soared Thursday morning on an FDA panel's recommendation on its obesity drug, with Michael Narachi, Orexigen CEO.

FDA questions effectiveness of weight loss pill

The Food and Drug Administration says a pill to treat obesity from Orexigen Therapeutics Inc. helped patients lose weight, though it didn't meet all the criterion set forth by the agency. Full story

Sponsored Links

Articles

Diet drug faces U.S. test after rivals fall short

Diet pill pulled from market for heart risk

Caffeine drove me insane, accused murderer says

Trial for diet drug halted early after suicides

Experimental diet pill shows promise, little risk

Drugmakers halt studies on two diet pills

Woman has 140-pound tumor removed

Video

  FDA panel split on withdrawing diet pill Meridia

The possibility that the popular diet drug may be restricted or pulled off the market entirely comes as a huge disappointment to those who say the drug helped them lose weight. NBC's Robert Bazell reports.